Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06230185 · ClinicalTrials.gov registry record
CtDNA Based MRD Testing for NAC Monitoring in TNBC
A clinical trial of TNBC - Triple-Negative Breast Cancer and Minimal Residual Disease, sponsored by Personalis.
- Recruiting
- Registry status
- 422
- Enrollment target
- 14
- Study locations
NCT06230185: Recruiting study of TNBC - Triple-Negative Breast Cancer and Minimal Residual Disease, sponsored by Personalis.
NCT06230185 is a study of TNBC - Triple-Negative Breast Cancer and Minimal Residual Disease that is actively recruiting participants, run by Personalis. The registered enrollment target is 422 participants, roughly in line with the 462-participant average among 22 other TNBC - Triple-Negative Breast Cancer trials with a reported enrollment target. The trial reports 14 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06230185, a study of TNBC - Triple-Negative Breast Cancer and Minimal Residual Disease, is actively recruiting participants, sponsored by Personalis.
- RECRUITING
- Registry status
- 422 participants
- Enrollment target
- 14
- Study locations
Study Summary
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results from this study aim to improve MRD detection and disease outcomes for future patients.
Primary Outcome
Evaluate the correlation of MRD detection by NeXT Personal CTA to pathological Complete Response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). The pCR is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes following completion of neoadjuvant systemic therapy.
Conditions Studied
Study Locations (14)
Florida
- Mount Sinai Medical Center of Florida - Miami Beach
- Comprehensive Hematology Oncology (ONare Alliance, LLC / Exigent Research, LLC - St. Petersburg
Arizona
- Arizona Oncology - Tucson
Colorado
- University of Colorado Cancer Center - Aurora
District of Columbia
- George Washington University - Washington D.C.
Illinois
- Illinois Cancer Care - Peoria
Louisiana
- Louisiana State University - New Orleans
Michigan
- Trinity Health-Michigan - Ypsilanti
Nebraska
- Nebraska Methodist - Omaha
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 422 participants |
| Start Date | 2023-11-09 |
| Est. Completion | 2025-12-31 |
What NCT06230185 shows while recruiting
NCT06230185 is an observational study that tracks outcomes without assigning an intervention. The registered 422 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 462-participant average among 22 other TNBC - Triple-Negative Breast Cancer trials with a reported enrollment target.
The record links to 2 conditions, with TNBC - Triple-Negative Breast Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT06230185 lists 14 locations in 13 states (Florida, Arizona, Colorado).
Frequently Asked Questions
What is clinical trial NCT06230185 about?
NCT06230185 is a clinical study titled "CtDNA Based MRD Testing for NAC Monitoring in TNBC". A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in stage I-III triple negative breast cancer (TNBC). Results ...
What is the current status of trial NCT06230185?
This trial is currently recruiting. The enrollment target is 422 participants. The study started on 2023-11-09. Estimated completion is 2025-12-31.
What conditions does trial NCT06230185 study?
This clinical trial studies the following conditions: TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease.
Who is sponsoring clinical trial NCT06230185?
This trial is sponsored by Personalis, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06230185 being conducted?
This trial has 14 study locations across Arizona, Colorado, District of Columbia, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for TNBC - Triple-Negative Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06230185's enrollment target sits among peer trials
422 5th of 22 higher than 18 of 22 other TNBC - Triple-Negative Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other TNBC - Triple-Negative Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
RECRUITING · Phase 1
-
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RECRUITING · Phase 2
-
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04763356 · 422 participants · NA
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
- NCT06837246 · 422 participants · NA
A Clinical Trial to Assess Cognitive Effects of Cognitive Nutritional Supplement in General Population
- NCT07298967 · 422 participants · NA
ORCHARDS-AIR Study
- NCT06935591 · 423 participants · NA
Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI